Compare IDEXX Laboratories, Inc. (IDXX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs LYFT Inc — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while LYFT Inc trades at $15.25 (market cap $5.86B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.6× LYFT Inc's market cap. Which is the better fit depends on your goals.
| IDXX | LYFT | |
|---|---|---|
Market Cap | $44.48B | $5.86B |
Sector | Health | Industrials |
52-Week High | $766.68 | $24.57 |
52-Week Low | $520.87 | $12.65 |
Enterprise Value | $45.38B | $5.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Lyft trades at $15.39, down 0.84% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company demonstrates strong revenue growth, reaching $6.32B in 2025 with a remarkable net income margin of 43.82%, though recent quarterly EPS results have been inconsistent with two misses and one beat. Analyst consensus leans neutral with 57.6% hold ratings but offers a $17.86 price target suggesting 16% upside potential.
Lyft presents a compelling valuation case with a low P/E of 2.27 and P/S of 0.98, supported by improving cash flow trends and strategic expansions into new markets. However, risks include competitive pressure from Uber, inconsistent earnings performance, and regulatory scrutiny over pricing practices. The upcoming Q2 2026 earnings report on August 6 will be critical for validating the company's growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
